Xenon gas inhalation

Phase 1Small molecule

GGeneral Biophysics LLC

Xenon gas inhalation is one of 48 small molecule programs targeting Safety and Efficacy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Safety and EfficacyRecruiting

Safety and EfficacyPhase 1

Recruiting

Competition

Competitive Landscape

131 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

3 2

Actemra

Roche

Phase 3

1 3

Humira

RRanbaxy Laboratories Limited

Phase 3

3 4

Rayos

RRoxane Laboratories

Phase 3

3 5

Empaveli

Apellis Pharmaceuticals

Phase 3

2 6

Gemzar

Johnson & Johnson

Phase 2

6 7

Fludara

Sanofi

Phase 2

5 8

CAB LA

GSK

Phase 3

1 9

Yervoy

Bristol-Myers Squibb

Phase 2

3 10

B/F/TAF

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation

Recruiting·GGeneral Biophysics LLC·Phase 1·NCT06945614·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Xenon gas inhalation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xenon gas inhalation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xenon gas inhalation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — General Biophysics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGeneral Biophysics LLC

Xenon gas inhalation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News